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Abstract
Background: Mammography and ultrasound are the gold standard imaging techniques for preoperative
assessment and for monitoring the efficacy of neoadjuvant chemotherapy in breast cancer. Maximum accuracy in
predicting pathological tumor size non-invasively is critical for individualized therapy and surgical planning. We
therefore aimed to assess the accuracy of tumor size measurement by ultrasound and mammography in a
multicentered health services research study.
Methods: We retrospectively analyzed data from 6543 patients with unifocal, unilateral primary breast cancer. The
maximum tumor diameter was measured by ultrasound and/or mammographic imaging. All measurements were
compared to final tumor diameter determined by postoperative histopathological examination. We compared the
precision of each imaging method across different patient subgroups as well as the method-specific accuracy in
each patient subgroup.
Results: Overall, the correlation with histology was 0.61 for mammography and 0.60 for ultrasound. Both
correlations were higher in pT2 cancers than in pT1 and pT3. Ultrasound as well as mammography revealed a
significantly higher correlation with histology in invasive ductal compared to lobular cancers (p < 0.01). For invasive
lobular cancers, the mammography showed better correlation with histology than ultrasound (p = 0.01), whereas
there was no such advantage for invasive ductal cancers. Ultrasound was significantly superior for HR negative
cancers (p < 0.001). HER2/neu positive cancers were also more precisely assessed by ultrasound (p < 0.001). The size
of HER2/neu negative cancers could be more accurately predicted by mammography (p < 0.001).
Conclusion: This multicentered health services research approach demonstrates that predicting tumor size by
mammography and ultrasound provides accurate results. Biological tumor features do, however, affect the
diagnostic precision.
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Background
Breast cancer remains the most common malignancy
among women with an incidence of about 70,000 cases per
year in Germany (http://www.krebsgesellschaft.de/basis-
informationen-krebs/krebsarten/brustkrebs.html). Distinct
biological subgroups of breast cancer show significantly dif-
ferent tumor growth and prognosis as well as therapeutic
options [1]. The invasive carcinoma of no special type
(NST), also known as invasive ductal carcinoma or ductal
carcinoma NOS (not otherwise specified), accounts for
about 70–80 % of breast cancers. Less common are invasive
lobular cancers with 10–15 % of all breast cancers and rare
subtypes such as medullary, tubular or mucinous carcin-
oma [2]. Using cDNA microarray analysis, Perou et al. de-
fined different biological subgroups of breast cancers with
impact on tumor biology and clinical appearance [1]:
Luminal A and B breast cancers as well as HER2/neu posi-
tive and basal like breast cancer. Gene expression profiling
is not yet part of routine tumor analysis But hormone re-
ceptor expression, HER2/neu overexpression and prolifera-
tion markers represent surrogate markers for biological
breast cancer subgroups.
Tumor resection is still essential for therapy concepts
in breast cancer care. In many cases, breast-conserving
surgery can be performed instead of mastectomy. In-
complete or marginal tumor resection requires a re-
resection. Imaging technologies are thus essential not
only for diagnosis but also for preoperative assessment
of breast cancer. Especially for non-palpable tumors, im-
aging plays an outstanding role.
Previous studies showed that mammography slightly
overestimates tumor size, whereas ultrasound tends to
underestimate tumor size [3]. Other groups found ultra-
sound to provide the more exact estimates for tumor
size [4]. In these studies, there was no separate evalu-
ation for the different biological subgroups of breast
cancer. A single-center retrospective study of 121 pa-
tients [5] found that ultrasound-based assessments tend
to underestimate in particular the size of invasive ductal
cancer with ductal carcinoma in situ and invasive lobular
as well as invasive ductal cancers. Bosch et al. published
a prospective study that found ultrasound to be the best
predictor of histological tumor size compared to mam-
mography and physical examination. As ultrasound
underestimated the tumor size, they suggested a formula
for calculating the probable histological tumor size: Sono-
graphic tumor size (mm) +3 mm [6]. Ultrasound seems to
be especially good in the assessment of tumors with less
than 30 mm diameter [7]. Ramirez and colleagues found
good correlations between ultrasound, mammography
and especially MRI with histological tumor size [8].
According to German guidelines for breast cancer
diagnostics and treatment, mammography is the stand-
ard imaging tool [9]. In case of high breast density (ACR
3–4), an ultrasound examination should be added to
achieve higher sensitivity [10]. Both mammography and
ultrasound are standard diagnostic tools for breast can-
cer assessment [11, 12]. The role of magnetic resonance
imaging (MRI) of the breast as preoperative assessment
is controversial: In a metaanalysis of 9 clinical studies,
Houssami and colleagues found that MRI did not reduce
re-excisions but significantly increased the rate of modi-
fied radical mastectomies (MRM) [13, 14]. They suggest
that a routine MRI in breast cancer patients could do
more harm than good [13]. Though preoperative bilat-
eral breast MRI could reduce the risk of a contralateral
cancer recurrence, Yi et al. could not find any difference
in local-regional recurrence rates [15].
The role of MRI in breast cancer imaging is still con-
troversial while ultrasound and mammography remain
the gold standard in care. We therefore aimed to investi-
gate accuracy of the gold standard imaging techniques
in a multicenter health services research approach inves-
tigating breast cancer imaging in a large daily routine
cohort of patients.
Methods
We retrospectively analyzed data from 6543 breast cancer
patients who were part of the BRENDA I study popula-
tion. Patients with unifocal, unilateral primary breast can-
cer were included in the BRENDA I study. Data were
collected from 1992 until 2008 at Ulm University Hospital
and from 2002 until 2008 in 16 associated German breast
cancer centers certified by the German Cancer Society.
The study protocol was approved by the Ethics committee
of the University of Ulm. Patients gave informed consent.
Data regarding maximum tumor diameter in preoperative
ultrasound, mammography, as well as histological tumor
diameter were collected.
Patients were excluded from the analysis if they re-
ceived neoadjuvant chemotherapy, if they suffered from
bilateral, multicenter or inflammatory breast cancer as
well as non-invasive tumors. In case of missing diagnos-
tic data, the patients were also excluded.
The maximum tumor diameter was measured by im-
aging as well as by pathologic examination. In case of
follow-up resections, tumor diameters were added ex-
cluding ductal carcinoma in situ (DCIS) and lobular car-
cinoma in situ (LCIS).
Endocrine responsiveness was categorized according
to the 2007 St. Gallen Consensus Criteria [16].
Statistical analysis
Statistical analysis was performed using R (version 3.1
[17]). Patient characteristics were described with percent-
ages, mean values and standard deviations. Precision (vari-
ability) and accuracy (systematic bias) of imaging methods
were analyzed separately. Precision of mammography and
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ultrasound tumor size measurements were assessed by
calculating Pearson’s correlation coefficient with histo-
logical tumor size. T-tests were used to compare the inde-
pendent correlation coefficients of the same imaging
method between patient groups. To compare the correl-
ation coefficients between imaging methods for the same
patient group, Williams’ test for the difference between
two dependent correlations sharing one variable (histo-
logical tumor size) was used. Accuracy of imaging
methods was assessed by their respective mean differences
to histology measurements. Numerical results were
complemented by visual evaluation of Bland-Altman plots
that show the difference between the tumor diameter as
measured by two methods against the mean of both
measurements.
To provide a detailed evaluation of precision of tumor
size measurements by mammography as well as ultra-
sound with respect to histology, we performed several
types of comparisons: A) Comparisons of each imaging
method across different patient groups. B) Comparison
between mammography and ultrasound within one pa-
tient group. Patient groups were defined by either their
age, or by different tumor characteristics like histological
sub-type. We finally compared the precision of the detec-
tion of a 20 mm tumor diameter cutoff (C.). The impact
of patient age on imaging was analyzed, respectively (D.).
Results
Description of the study population
Six thousand five hundred forty-three patients were eli-
gible for the study. The mean age at diagnosis was 61.9
(SD 13.0 years). Three thousand eight hundred fifty-nine
patients were stage pT1 , 2469 with pT2 and 217 pa-
tients with pT3. Four thousand two hundred ten pa-
tients (64.3 %) showed pN0 status. 10.8 % of the tumors
were graded as G1, the majority of tumors were G2
(61.8 %) and 27.3 % were G3 carcinomas. 14.4 % of the
tumors were hormone receptor (HR) negative. 14.8 % of
the tumors overexpressed HER2.
Comparisons of each imaging method across different
patient groups
Mean difference between sonographic and histological
tumor size The distributions of measured tumor size
were generally unimodal and slightly right-skewed. The
mean tumor diameter determined by ultrasound was
18.3 mm (SD 9.6 mm), whereas the histological mean
tumor diameter was 20.8 mm (SD 12.3 mm). Data are
summarized in Table 1. A Bland-Altman plot (Fig. 1a)
indicates that measurement differences were propor-
tional to tumor size with invasive lobular tumors being
over-represented among tumors that are underestimated
by ultrasound: Among 198 tumors underestimated by
more than 20 mm, 68 (34 %) were invasive lobular can-
cers. Among 62 tumors overestimated by ultrasound by
more than 20 mm, only 4 (6 %) were invasive lobular
cancers. Among 5642 tumors neither over- nor underes-
timated by more than 20 mm, 665 (12 %) were invasive
lobular cancers (p < 0.001).
Overall, ultrasound underestimated the histological
tumor size with a mean difference of 2.5 mm. This result
also appeared in HR positive and HR negative tumors as
well as in invasive ductal and invasive lobular cancers.
There was a tendency towards decreasing sonographic
accuracy in G3 high grade cancers.
Ultrasound accuracy was strongly dependent on tumor
size: In pT1 cancers, the sonographic tumor diameter
was higher than the histological tumor diameter. pT2
and pT3 cancers always had larger histological tumor di-
ameters than determined by ultrasound.
Mean difference between mammographic and
histological tumor size The overall mean histological
diameter for patients examined by mammography was
21.0 mm, and the mean mammographic diameter was
20.4 mm. An overview of the mammography data is
shown in Table 2. A Bland-Altman plot (Fig. 1b) indi-
cates that measurement differences were proportional to
tumor size with invasive lobular tumors being over-
represented among tumors that are underestimated by
mammography: Among 110 tumors underestimated by
more than 20 mm, 28 (25 %) were invasive lobular can-
cers. Among 110 tumors overestimated by mammog-
raphy by more than 20 mm, only 12 (11 %) were
invasive lobular tumors. Among 4010 tumors neither
over- nor underestimated by more than 20 mm, 434
(11 %) were invasive lobular cancers (p < 0.001).
In both invasive ductal and invasive lobular cancer size
was overall underestimated by mammography.
For mammography, tumor size was an important fac-
tor for the observed accuracy. pT1 cancers with a mean
histologic diameter of 13.5 mm were overestimated in
mammography while the opposite was true for pT2 and
pT3. The difference peaked in the pT3 group with a
mean histologic diameter of 62.6 mm and a mean differ-
ence of 18.3 mm. Similarly, G1 cancers with a mean
histological tumor diameter of 15.0 mm appeared larger
in mammography whereas the size of G2 and G3 can-
cers was underestimated. Again, the peak mean differ-
ence was found in G3 cancers.
Comparison between mammography and ultrasound within
one patient group
The correlation coefficients between histology, ultra-
sound and mammography for the respective subgroups
are shown in Table 3.
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As we sought to evaluate the precision of different
diagnostic methods in breast cancer subgroups, we com-
pared the correlations of ultrasound with histology, of
mammography with histology and, respectively, of ultra-
sound with mammography.
Overall, the analyses comparing histology and ultra-
sound or histology and mammography showed no sig-
nificant differences between the two non-invasive
techniques (p = 0.18).
Both, ultrasound and mammography showed signifi-
cantly higher correlations with histology in invasive
ductal compared to invasive lobular cancers (p = 0.002,
3.07/p = 0.008).
Ultrasound and histology further showed a signifi-
cantly better correlation for pT2 compared to pT1
cancers (p = 0.001). This correlation was also highly sig-
nificantly superior for pT2 compared to pT3 cancers
(p = 0.0002). Equivalent results could be detected in
the correlation of mammography and histology,
which was also significantly higher for pT2 compared
to pT1 (p < 0.001) or compared to pT3 (p = 0.026).
In the subgroup of invasive lobular cancers, hist-
ology showed a significantly higher correlation with
mammography than with ultrasound (p = 0.01). There
was no such difference in the invasive ductal cancer
subgroup.
For HR negative cancers, ultrasound showed a signifi-
cantly higher correlation with histology (p < 0.001). Size
estimates by mammography were, however, significantly
more accurate for HR positive than for HR negative

















Overall 20.78 18.25 2.534 21.08 12.29 9.629 5902
Endocrine non-responsive 23.77 21.10 2.666 17.24 13.98 10.205 848
Incomplete endocrine responsive 19.88 18.18 1.702 16.91 11.60 10.408 1224
Highly endocine responsive 20.43 17.62 2.811 23.44 12.00 9.078 3817
Not applicable 14.69 23.46 −8.769 −29.05 12.85 16.179 13
Ductal invasive 20.41 18.31 2.097 18.28 11.69 9.663 4257
Lobular invasive 23.42 17.72 5.699 43.13 14.97 9.627 737
G1 15.03 14.48 0.5521 11.15 9.824 9.191 652
G2 20.08 17.61 2.4675 21.97 11.678 9.317 3636
G3 24.69 21.21 3.4854 23.08 13.289 9.697 1614
pT1 13.52 14.03 −0.5067 6.024 5.159 7.066 3450
pT2 28.45 23.34 5.1141 35.658 6.989 8.347 2265
pT3 61.84 34.45 27.3904 122.220 17.761 16.055 187
Age <50 years 20.06 17.70 2.353 21.99 12.40 9.127 1295
Age 50–70 years 19.65 17.12 2.509 21.80 11.91 9.477 3042
Age >70 years 23.00 10.50 12.500 93.33 21.21 6.364 2
Fig. 1 Difference between sonographic, mammographic tumor size. Bland-Altman Diagrams of the Differences between tumor size as measured
by ultrasound (a) and mammography (b) plotted against their respective mean value. Histological subtypes are indicated
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non-responsive cancers, as evidenced by the superior
correlation with histology (p = 0.0003).
Still, in both HR negative and HR positive cancers,
mammography was inferior to ultrasound regarding the
correlation with histology (p < 0.001/p < 0.001 ).
The correlation of mammography with histology was,
however, significantly better for the HER2/neu negative
than for the HER2/neu positive subgroup (p < 0.001).
For the HER2/neu negative subgroup, mammography
data showed a significantly higher correlation with hist-
ology whereas ultrasound was less precise (p < 0.001). In
the HER2/neu positive subgroup, however, ultrasound
came significantly closer to the histological size deter-
mination (p = 0.0001).
Ultrasound tends to underestimate the tumor size in
invasive lobular cancers. Invasive lobular cancers showed
a significantly higher percentage of grossly
underestimated tumors (>35 mm difference to histology).
Precision of ultrasound and mammography for 20 mm
cutoff detection
For further therapy, 20 mm tumor size is an important
cutoff. We thus analyzed the sensitivity of mammog-
raphy and ultrasound in detecting this tumor size cutoff.
For detection of tumor sizes over 20 mm, ultrasound
was slightly more specific (0.752 versus 0.703) and
slightly more sensitive than mammography (0.824 versus
0.799). Ultrasound showed a higher cutoff detection rate
(0.225 versus 0.172), superior positive predictive (0.555
versus 0.424) values. Mammography was superior only
at negative predictive values (0.919 versus 0.927).
Patient age impacts both ultrasound and mammography
precision
The results in relation to patient age are shown in
Table 4. As breast density decreases in older patients, we
analyzed the results in different age groups. Patients
aged <50 years, 50–70 years and >70 years were com-
pared respectively.
Higher patient age correlated with higher tumor size
and respective T stage. Patients aged <50 years showed
more HR negative cancers compared to older patients.
The percentage of invasive ductal and lobular cancers
was comparable in all age groups.
Both mammography and ultrasound were highly sig-
nificantly superior for patients aged >70 years compared
to patients aged 50–70 years (p < 0.01). Both mammog-
raphy and sonography achieved the lowest precision in
patients aged <50 years compared to patients aged 50–
70 years (p = 0.024/p = <0.001).
Still, the histology correlation of mammography and
ultrasound did not significantly differ in any age group.
Discussion
In our study, the overall correlation between histology and
mammography was 0.61 for mammography and 0.60 for
ultrasound and thus did not show any significant


















Overall 21.01 20.41 0.6012 14.85 12.5 11.91 4230
Endocrine non-responsive 23.33 23.42 −0.09015 11.08 13.603 13.431 599
Incomplete endocrine responsive 20.45 20.05 0.39892 13.50 12.347 11.308 930
Highly endocine responsive 20.70 19.87 0.82993 16.15 12.246 11.663 2693
Not applicable 17.50 18.62 −1.125 16.52 7.426 7.425 8
Ductal invasive 20.59 20.30 0.2864 12.99 11.63 11.55 3132
Lobular invasive 23.61 20.68 2.9325 31.22 15.97 13.32 474
G1 15.00 15.44 −0.435 7.551 10.66 10.22 423
G2 20.16 19.65 0.5078 15.023 11.44 11.32 2623
G3 25.05 23.87 1.1782 17.078 14.02 12.78 1184
pT1 13.52 15.13 −1.612 3.881 5.242 8.134 2408
pT2 28.51 26.11 2.399 24.427 6.995 10.127 1693
pT3 62.6 44.28 18.318 93.960 21.265 23.583 129
Age <50 years 21.11 20.05 1.0606 16.54 12.54 11.53 808
Age 50–70 years 19.65 19.10 0.5579 16.12 12.18 11.49 2210
Age >70 years 23.44 23.06 0.3757 11.44 12.67 12.47 1211
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difference in terms of precision of tumor diameter meas-
urement (p = 0.18). Both ultrasound and mammography
did show a significantly higher correlation with histo-
logical tumor diameter in invasive ductal compared to in-
vasive lobular cancers (p = 0.002 / p = 0.008). For invasive
lobular cancers, mammography turned out to be superior
to ultrasound with respect to the correlation with histo-
logical tumor diameter (p = 0.01), whereas there was no
advantage in the invasive ductal cancer subgroup. The
analysis was focused on tumors detected by respective im-
aging. pT2 cancers could generally be assessed more pre-
cisely by both ultrasound and mammography whereas
pT1 or pT3 showed more deviation. This result could be
biased by the more accurate palpation of T2 tumors.
While HR positive cancers did not show a difference be-
tween the precision of ultrasound and mammography, HR
negative cancers show a highly significant advantage for
ultrasound (p < 0.001). HER2/neu positive cancers also
showed the superiority of ultrasound (p < 0.001) whereas
mammography was superior in predicting the size of
HER2/neu negative cancers (p < 0.001).
In line with Gruber et al. [5], we found ultrasound to
underestimate histological tumor diameter. MRI data
were not available for our study. Nevertheless, by com-
paring ultrasound and mammography data with histo-
pathological findings, the precision of imaging-based
tumor size determination could be assessed for the vari-
ous biological subclasses of breast cancer. This showed
that HR expression as well as HER2/neu overexpression
impacts the precision achieved by imaging.
Hieken et al. [4] published that both ultrasound and
mammography underestimated tumor size. In 180 cases





Histology – Ultrasound 0.5981 5902
Histology – Mammography 0.605 4230
Ultrasound – Mammography 0.7369 3757
Correlation in ductal invasive cancer
Histology – Ultrasound 0.6045 4257
Histology – Mammography 0.6157 3132
Ultrasound – Mammography 0.7319 2784
Correlation in lobular invasive cancer
Histology – Ultrasound 0.5209 737
Histology – Mammography 0.5271 474
Ultrasound – Mammography 0.7012 424
Correlation for pT1
Histology – Ultrasound 0.3178 3450
Histology – Mammography 0.2528 2408
Ultrasound – Mammography 0.5922 2121
Correlation for pT2
Histology – Ultrasound 0.3938 2265
Histology – Mammography 0.3864 1693
Ultrasound – Mammography 0.6349 1534
Correlation for pT3
Histology – Ultrasound 0.1344 187
Histology – Mammography 0.1989 129
Ultrasound – Mammography 0.5527 102
Correlation for endocrine non-responsive
cancer (HR negative)
Histology – Ultrasound 0.6427 848
Histology – Mammography 0.5252 599
Ultrasound – Mammography 0.7436 538
Correlation for incomplete endocrine responsive
cancer (HR positive)
Histology – Ultrasound 0.5212 1224
Histology – Mammography 0.5781 930
Ultrasound – Mammography 0.7092 811
Correlation for highly endocrine responsive cancer
(HR positive)
Histology – Ultrasound 0.6124 3817
Histology – Mammography 0.6334 2693
Ultrasound – Mammography 0.7407 2401
Correlation for HER2/neu positive cancer
Histology – Ultrasound 0.6345 797
Histology – Mammography 0.4375 565
Ultrasound – Mammography 0.7408 507
Correlation for HER2/neu negative cancer
Histology – Ultrasound 0.5958 4587
Table 3 Correlation of tumor diameter in histology, Ultrasound
and mammography (Continued)
Histology – Mammography 0.6466 3278
Ultrasound – Mammography 0 0.7332 2956
Correlation for patients aged <50 years
Histology - Ultrasound 0.4658 1295
Histology - Mammography 0.5158 808
Ultrasound - Mammography 0.6922 729
Correlation for patients aged 50–70 years
Histology - Ultrasound 0.5970 3042
Histology - Mammography 0.5809 2210
Ultrasound - Mammography 0.7250 1941
Correlation for patients aged >70 years
Histology - Ultrasound 0.6700 1563
Histology - Mammography 0.6752 1211
Ultrasound - Mammography 0.7583 1086
Correlations with histology are shown for pairwise data, whereas correlations
between Ultrasound and mammography required complete datasets
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of invasive breast cancers, they found ultrasound to be
more accurate. In clear contrast to their results, we
could show distinct differences of imaging precision in
invasive ductal and invasive lobular cancers and thus
provide evidence for the importance of biological cancer
subgroups for imaging.
Dummin and colleagues [3] found, that ultrasound un-
derestimates breast cancer size. Mammography turned
out to be the most precise tool for predicting histological
tumor size. However, they did not compare different bio-
logical cancer subgroups regarding the correlations be-
tween histological, sonographic and mammographic
tumor diameter.
It has to be considered that our retrospective study is
an analysis of longitudinal study data. Further studies
should investigate not only the maximum tumor diam-
eter but for example three-dimensional tumor size. Im-
proved ultrasound technologies such as 3D ultrasound
make this possible. Our analysis is based on a large set
of patient data, even though ultrasound and mammog-
raphy data were not available for all patients. Further-
more, there was no information about breast density in
imaging according to the American college of radiology
(ACR). A great advantage of the longitudinal BRENDA I
study is that the data were collected under realistic daily
routine conditions. Precise data also exist for exact
histological tumor diameter and all histological subtypes
of breast cancer are represented. We could thus show
that both ultrasound and mammography are reasonably
precise in assessing tumor size. Mammography seems fa-
vorable for HER2/neu negative and invasive lobular can-
cers. Ultrasound is more precise for HER2/neu positive
and HR negative invasive ductal cancers.
Conclusion
We provide evidence that the prediction of tumor
size by ultrasound and mammography in breast can-
cer is reliable in this large multicentered daily routine
cohort of primary breast cancer patients. Neverthe-
less, our data suggest that inherent features of indi-
vidual tumor subgroups influence the non-invasive
assessment of tumor size. Taking this into consider-
ation may further improve the interpretation of im-
aging data for therapeutic decisions.
Table 4 Patient age impacts both ultrasound and mammography precision
Age (years) versus T stadium pT1 pT2 pT3
<50 0.63591 0.33570 0.02839
50-70 0.63337 0.33754 0.02908
>70 0.46590 0.48902 0.04509
Age (years) versus Grading G1 G2 G3
<50 0.095 0.530 0.375
50-70 0.122 0.627 0.251
>70 0.092 0.674 0.234
Age (years) versus HR expression HR negative HR incompletely responsive HR positive
<50 0.20 0.23 0.57
50-70 0.14 0.21 0.65
>70 0.10 0.21 0.69












Relative Quantifications for T stadium, Grading, HR expression, HER2/neu expression or histological subtype in relation to age are shown
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